Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation.

Clinical and Experimental Immunology
Z WangQ Wang

Abstract

CD4(+)CD25(+) forkhead box P3 (FoxP3)(+)regulatory T (T(reg)) cells are generated and play a key role in the induction and maintenance of transplant tolerance in organ recipients. It has been proposed that interleukin (IL)-2/IL-2 receptor (IL-2R) signalling was essential for the development and proliferation of antigen-activated T cells that included both effector T cells and T(reg) cells. Basiliximab (Simulect), a chimeric monoclonal antibody directed against the alpha-chain of the IL-2R (CD25), can be expected to not only affect alloreactive effector T cells, but also reduce the number and function of T(reg) cells. We therefore examined the effect of basiliximab induction therapy on the number and function of the T(reg) cells in renal recipients. Basiliximab decreased the percentage of CD4(+)CD25(+)T cells, but failed to influence the percentage of CD4(+)FoxP3(+) T(reg) cells. The cellular CD25 expression was decreased significantly by basiliximab injection, but CD4(+)CD25(+) T cells was not depleted from the circulating pool through monoclonal antibody activation-associated apoptosis. Functional analysis revealed that inhibitory function of T(reg) cells from recipients with basiliximab injection was not significantly differe...Continue Reading

References

Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·C Baecher-AllanD A Hafler
Aug 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S GregoriL Adorini
Jan 11, 2003·Science·Shohei HoriShimon Sakaguchi
Feb 15, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·David S GameRobert I Lechler
Mar 23, 2005·Immunity·Jason D FontenotAlexander Y Rudensky
Oct 18, 2005·Nature Immunology·Jason D FontenotAlexander Y Rudensky
Oct 26, 2005·Nature Immunology·Karsten KretschmerHarald von Boehmer
Mar 7, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam P KohmStephen D Miller
May 25, 2006·Human Immunology·P van de LindeB O Roep
Nov 18, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·E KreijveldI Joosten
Jan 16, 2007·Nature·Marc A GavinAlexander Y Rudensky
Feb 9, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·F VeroneseR B Colvin
Feb 13, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J H L VelthuisC C Baan
Mar 23, 2007·Nature·Masahiro OnoShimon Sakaguchi

❮ Previous
Next ❯

Citations

Nov 26, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Willy AasebøHallvard Holdaas
Dec 15, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Eva KrystufkovaOndrej Viklicky
Aug 7, 2010·PloS One·Marie-Ghislaine de Goër de HerveYassine Taoufik
Jul 15, 2011·Immunotherapy·Martijn W F van den Hoogen, Luuk B Hilbrands
Mar 19, 2013·International Immunopharmacology·Xiao-Jun WangPiotr Witkowski
Apr 29, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anne P BouvyCarla C Baan
Nov 26, 2013·Expert Opinion on Drug Safety·Claudio Ponticelli
Mar 1, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Stephan Schlickeiser, Birgit Sawitzki
Apr 8, 2010·Pediatric Clinics of North America·Simon UrschelLori J West
Jun 7, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Norberto PericoGiuseppe Remuzzi
Jul 16, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·V D K D SewgobindC C Baan
May 16, 2012·European Journal of Immunology·Todd A TriplettAndrew D Weinberg
Mar 12, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·T CrepinJ Bamoulid
Dec 3, 2009·Transplant International : Official Journal of the European Society for Organ Transplantation·Florian Wolfgang Rudolf VondranReinhard Schwinzer
Oct 25, 2016·Transplantation·Akiko FurukawaQizhi Tang
Dec 11, 2019·Antibodies·Veena A Thomas, Joseph P Balthasar
Jan 2, 2021·Journal of Hematology & Oncology·Katarzyna IżykowskaGrzegorz K Przybylski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Jeffrey A BluestoneF Vincenti
Transplant International : Official Journal of the European Society for Organ Transplantation
Florian Wolfgang Rudolf VondranReinhard Schwinzer
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
D D BloomS J Knechtle
© 2021 Meta ULC. All rights reserved